Results of Radiotherapy With and Without Chemotherapy for Esophageal Cancers

방사선치료 단독(25명) 또는 화학요법과 방사선 병용치료(37명)를 받은 62명의 식도암환자에 대한 후향성분석의 결과는 다음과 같다. 방사선 단독치료를 받은환자중 14명이, 병용치료를 받은환자중 25명이 계획된 치료를 끝내었다. 추적기간은 6일에서 50개월 이었다. 39명중 완전관해는 3명(8%)에서, 부분관해는 28명(72%)에서 보였다. 중앙 생존기간은 11개월이었고, 1년 및 2년 생존율은 각각 48.6%, 13%이었다. 나이와 병기가 예후에 유의한 영향을 미쳤다. 병기에 따른 1년 생존율은 1기에서 70.1%, 2에서 47.6%, 3기에서는 28.4%이었고, 중앙생존기간은 1기에서 19개월, 2기에서는 11개월, 3기에서 6개월 원격전이가 있는 3기에서는 5.5개월 이었다. 나이에 따른 1년 생존율은 55세 이상에서 69.6%, 54세 이하에서 0%이었다. 치료방법, 종양의 위치, 원발병소의 반응에 따른 생존률에는 유의한 차이가 없었다.

This is a retrospective study of 62 patients with unresected squamous cell carcinoma of the esophagus treated by radiotherapy alone (25 patients) or combined chemontherapy and radiotherapy (37 patients). Of these, 14 of 25 patients treated by radiation therapy alone and 25 of 37 patients treated by combined chemotherapy and radiotherapy completed radiotherapy consisting of 55 to 60 Gy in 5to 6 weeks and were analyzed for local control rate and survival rate. Follow up ranged from 6days to 58months. Three(8%) of 39 patients had a complete response, twenty-eight(72%) a partial response and eight (20%) minimal or no response. Overall median survival was 11 months for all stages. The 1 year and 2 year actuarial survival rates were 48.6% and 13% respectively. Age and stage had prognostic significances (p<0.05, p<0.05 respectively). The 1 year survival rate was 70.1% for stageⅠ, 47.6% for stageⅡ, and 28.4% for stageⅢ. The median survival was 19 months for stageⅠ, 11months for stageⅡ, 6months for stageⅢ, and 5.5months for stageⅢ with distant metastases. The 1 year survival rate of patients 55 years and above was 69.6%, 54 years and below was 0%. There was no significant difference in survival rate between treatment modalities, locations of tumor, and responses of tumor.